Pharmaceutical company 4D pharma has received clearance from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Health Products Regulatory Authority (HPRA) to commence the Phase II study of 'Blautix', it announced on Wednesday. The AIM-traded company said Blautix is a live biotherapeutic for the treatment of irritable bowel syndrome (IBS), with the trial to take place at sites in the UK and Ireland. It followed an announcement made by the firm in May that the US Food and Drug ...Den vollständigen Artikel lesen ...